Walleye Capital LLC Exelixis, Inc. Call Options Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $1.08 Million - $1.36 Million	49,400 New	49,400 $1.28 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $143,207 - $169,903	7,100 New	7,100 $168,000
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $79,968 - $95,508	4,200 New	4,200 $91,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $721,554 - $1.09 Million	-49,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $755,985 - $942,611	49,900 New	49,900 $879,000
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $304,096 - $389,580	-17,200 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $34,074 - $44,550	1,800 Added 11.69%	17,200 $368,000
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $301,840 - $381,304	15,400 New	15,400 $367,000

500

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.2B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.